Leading players lose US lacosamide appeal
Several of the world’s leading generics players, including Teva, Mylan, Apotex and Aurobindo, have failed to convince the US Court of Appeals that the sole US patent listed against UCB’s Vimpat (lacosamide) tablets is invalid. Reissued US drug-substance patent RE38,551 protects until 17 March 2022 the Vimpat epilepsy brand that experienced a 19% rise in US sales last year to C746 million (US$874 million).
You may also be interested in...
UCB’s Vimpat blockbuster has finally fallen to generic competition in the US, after its intellectual property was skewered by ANDA sponsors as part of a failed challenge before the US Supreme Court in 2018 and 2019.
This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.
Three generics firms have failed in their latest attempt to invalidate a patent protecting UCB’s lacosamide-based Vimpat epilepsy brand until 2022.